GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

GETI.B

209.4

+0.29%↑

BIOAB

290

-7.29%↓

VITR

137

+1.78%↑

EKTA.B

44.3

-1.6%↓

AMBEA

126.1

+0.08%↑

Strona główna・Stock List・Camurus AB

Camurus AB

Closed

723.5 -0.07

Buy Sell

Overview

Share price change

24h

Current

Min

716

Max

730

Key metrics
By Trading Economics
Income	53M 292M
Sales	117M 676M
P/E Sector Avg	59.883 35.733
EPS	4.08
Profit margin	43.235
Employees	267
EBITDA	54M 315M

Market Stats
By TradingEconomics
Market Cap	1.8B 43B
Previous open	723.57
Previous close	723.5

Camurus AB Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 wrz 2025, 16:09 UTC

Acquisitions, Mergers, Takeovers

BBVA Clears Last Hurdle to Open $17.4 Billion Bid to Sabadell Shareholders -- 2nd Update

5 wrz 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 wrz 2025, 20:37 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 wrz 2025, 20:37 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 wrz 2025, 20:36 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 wrz 2025, 20:36 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 wrz 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 wrz 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 wrz 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 wrz 2025, 20:20 UTC

Earnings

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 wrz 2025, 19:23 UTC

Market Talk

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 wrz 2025, 19:22 UTC

Earnings

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 wrz 2025, 19:17 UTC

Market Talk

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 wrz 2025, 18:59 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 wrz 2025, 18:35 UTC

Market Talk

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 wrz 2025, 17:25 UTC

Market Talk

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 wrz 2025, 17:20 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 wrz 2025, 17:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 wrz 2025, 17:17 UTC

Market Talk

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 wrz 2025, 17:03 UTC

Market Talk

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 wrz 2025, 16:39 UTC

Acquisitions, Mergers, Takeovers

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 wrz 2025, 16:39 UTC

Acquisitions, Mergers, Takeovers

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 wrz 2025, 16:39 UTC

Acquisitions, Mergers, Takeovers

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 wrz 2025, 16:39 UTC

Acquisitions, Mergers, Takeovers

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 wrz 2025, 16:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

5 wrz 2025, 16:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Energy Roundup: Market Talk

5 wrz 2025, 16:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 wrz 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 wrz 2025, 16:16 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

5 wrz 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

Camurus AB Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.